84 - HIV Debate Session: Squabbles Among Friends in HIV Case

Thursday, October 20, 2022

3:15 PM – 4:30 PM US ET

Location: 146 ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Interactive Moderator(s)

Jose Castillo-Mancilla, MD

Associate Professor
University of Colorado-AMC

Disclosure(s): Gilead Science: Grant/Research Support (Ongoing); NIH/NIAID: Grant/Research Support (Ongoing)

Slides
Darcy Wooten, MD, MS

Associate Professor of Medicine, Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Sara Bares, MD

Associate Professor, Division of Infectious Diseases
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska, United States

Disclosure(s): Gilead Science: Advisor/Consultant (Terminated); Janssen Infectious Disease: Grant/Research Support (Ongoing); The GSK group of companies: Grant/Research Support (Ongoing)

Slides
Aadia Rana, MD

Associate Professor of Medicine
University of Alabama-Birmingham School of Medicine
Birmingham, AL, United States

Disclosure(s): Merck and Company, Inc.: Grant/Research Support (Terminated)
Hillary Dunlevy, MD, MPH

Assistant Professor
University of Colorado
Aurora, CO, United States

Disclosure(s): Gilead Biosciences: Grant/Research Support (Ongoing); Janssen Infectious Disease: Advisor/Consultant (Ongoing)

Slides
Grant Ellsworth, MD, MS

Assistant Professor of Medicine
Weill Cornell Medicine
New York, NY, United States

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Jose Castillo-Mancilla, MD: Gilead Science: Grant/Research Support (Ongoing); NIH/NIAID: Grant/Research Support (Ongoing)

Darcy Wooten, MD, MS: No financial relationships to disclose

Sara H. Bares, MD: Gilead Science: Advisor/Consultant (Terminated); Janssen Infectious Disease: Grant/Research Support (Ongoing); The GSK group of companies: Grant/Research Support (Ongoing)

Aadia Rana, MD: Merck and Company, Inc.: Grant/Research Support (Terminated)

Hillary Dunlevy, MD, MPH: Gilead Biosciences: Grant/Research Support (Ongoing); Janssen Infectious Disease: Advisor/Consultant (Ongoing)

Grant Ellsworth, MD, MS: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss whether or not LA ART is ready for use in high-risk populations
discuss the pros and cons of rapid ART

Presentations:

3:15 PM – 3:50 PM US ET

LA ART: Ready for Use in High-Risk Populations? Pro/Con
Speaker: Aadia Rana, MD – University of Alabama-Birmingham School of Medicine
Speaker: Sara H. Bares, MD – University of Nebraska Medical Center
3:50 PM – 4:25 PM US ET

Anal Cancer Screening and Prevention: Pro/Con
Speaker: Hillary Dunlevy, MD, MPH – University of Colorado
Speaker: Grant Ellsworth, MD, MS – Weill Cornell Medicine